At the IGTP TODAY
Measuring the levels of vitronectin in urine could improve the detection of kidney fibrosis, according to scientists from the IGTP and HUGTiP.
_1733134235.jpg)
New study, in collaboration with GCAT, explores the association between different environmental exposures and Long-COVID in a Catalan population cohort.
_1732028870.jpg)
The IGTP is leading an innovative project on youth sexual health and participating in a second project funded by La Marató 2023, which has enabled the promotion of 26 research projects on sexual and reproductive health, led by 52 research teams. Yesterday, these teams received their awards at an event held at TV3. Of the funded projects, 10 are individual, and 16 are coordinated between two or more research centres.
The participation of the GCAT|Genomes For Life cohort in the CORDELIA consortium represents a strategic step to enhance and expand the impact of population research on the IGTP campus. This collaboration is part of the transversal CORE program, aimed at fostering innovative and translational research, implementing new knowledge in clinical practice, and improving population health.
Researchers at IGTP and IISPV have conducted a review on the therapeutic potential of extracellular vesicles in inflammatory bowel disease. While this approach remains in the early stages of research, ongoing clinical studies for various diseases already support its viability.
Researchers at IGTP and HUGTiP have reinforced their leading role in infectious disease research by characterising and developing a new study model using Drosophila, which will enable the evaluation of various infectious agents.
To mark World Diabetes Day and as part of the IA4T2D project, the GCAT|Genomes for Life team at Germans Trias i Pujol Research Institute (IGTP) has conducted interviews with leading scientists in the field of diabetes. Each expert shared valuable insights into the causes, challenges, and potential solutions for managing and preventing this widespread disease.
Researchers from five Catalan research centres have collaborated on a large-scale genetic study, identifying genetic loci and therapeutic targets that could reduce cardiovascular risk by modulating blood metabolites.
A team of researchers including the GRENBA group at IGTP has identified a promising therapy based on antimiRs to treat myotonic dystrophy type 1 (DM1). The results of their research have just been published in Science Advances.
Researchers from Barcelona's Germans Trias i Pujol Institute and Josep Carreras Leukaemia Research Institute have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results, published in the Journal of Clinical Investigation, builds on two harmonized Phase I clinical trials funded by the European Union, focusing on the use of Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The team is now preparing to move into Phase II trials to further explore these findings.
